DEPLOYDatabase

Company

Asensus Surgical

Asensus Surgical is an American surgical robotics company based in Durham, North Carolina, developing the Senhance robotic surgical system for minimally…

Track Asensus SurgicalGet notified of verified changes
Founded
2006
HQ
Durham, NC
Status
acquired by Karl Storz (Aug 2024; ~$95M; delisted)
Models
1

Verified profile

  • 4

    Sources on record

  • 1

    Tracked changes

  • Updated 1 month ago

    Last verified change

Overview

Asensus Surgical is an American surgical robotics company based in Durham, North Carolina, developing the Senhance robotic surgical system for minimally invasive abdominal surgery, with AI-powered surgical intelligence and augmented reality visualization.

Verified record

Verified deployments
None on file
Active incidents
2 incidents on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Current platform

Senhance

Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value. The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable. On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.

surgicalView model →

Current leadership (1)

Former / Previously (1)

Safety record

2 recalls on record (2 critical). Most recent: Sep 2023.

critical
2

Most recent: Sep 2023

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Incidents affecting Asensus Surgical (2)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Peer companies